

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
11 November 2004 (11.11.2004)

PCT

(10) International Publication Number  
**WO 2004/096807 A3**

(51) International Patent Classification<sup>7</sup>: **C07D 487/04**,  
471/04, A61K 31/4985, A61P 31/18

(21) International Application Number:  
PCT/EP2004/050621

(22) International Filing Date: 27 April 2004 (27.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/465,987 28 April 2003 (28.04.2003) US  
03101164.6 28 April 2003 (28.04.2003) EP

(71) Applicant (for all designated States except US): **TI-  
BOTEC PHARMACEUTICALS LTD.** [IE/IE]; Little  
Island, Co Cork (IE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **VERSCHUEREN**,  
Wim, Gaston [BE/BE]; De Wittestraat 5, B-2600




Berchem (BE). **DIERYNCK, Inge** [BE/BE]; Moonsstraat  
38, B-2018 Antwerpen (BE). **SURLERAUX, Dominique**,  
Louis, Nestor, Ghislain [BE/BE]; Rue de la Scaillée 13,  
B-1440 Braine-le-Château (BE). **DAEYAERT, Frederik**,  
Frans, Desiré [BE/BE]; Stijn Streuvelsstraat 64, B-2340  
Beerse (BE).

(74) Agent: **DAELEMANS, Frank**; Tibotec-Virco Comm.  
VA, Generaal De Wittelaan L11 B3, B-2800 Mechelen  
(BE).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

[Continued on next page]

(54) Title: HIV INTEGRASE INHIBITORS



(57) Abstract: The present invention concerns the compounds having the formula (I), N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof wherein (a) or (b); A, together with the two carbons of the phenyl ring to which it is attached forms a monocyclic aryl or a monocyclic Het<sup>2</sup>; R<sup>1</sup> is hydrogen, halo, nitro, cyano, sultam, sultim, C<sub>3-7</sub>cycloalkyl, C(=O)-R<sup>5</sup>, S(=O)<sub>2</sub>-R<sup>6</sup>, OR<sup>7</sup>, NR<sup>8</sup>R<sup>9</sup>, C(=NR<sup>8</sup>)-R<sup>5</sup>, optionally polysubstituted C<sub>1-6</sub>alkyl, optionally polysubstituted C<sub>2-6</sub>alkenyl or optionally polysubstituted C<sub>2-6</sub>alkynyl; R<sup>2</sup> is hydrogen, C<sub>3-7</sub>cycloalkyl, aryl, Het<sup>1</sup>, Het<sup>2</sup>, C(=O)-R<sup>5</sup>, S(=O)<sub>2</sub>-R<sup>6</sup> OR<sup>7</sup>, NR<sup>8</sup>R<sup>9</sup>, C(=NR<sup>8</sup>)-R<sup>5</sup>, or optionally polysubstituted C<sub>1-6</sub>alkyl, optionally polysubstituted C<sub>2-6</sub>alkenyl or optionally polysubstituted C<sub>2-6</sub>alkynyl. It further relates to their use as HIV integrase inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with other anti-retroviral agents, and to their use in assays as reference compounds or as reagents.



(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) **Date of publication of the international search report:**  
6 January 2005

(48) **Date of publication of this corrected version:**  
22 September 2005

(15) **Information about Correction:**  
see PCT Gazette No. 38/2005 of 22 September 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.